secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapForce Inc. (CFOR)
CIK:        0001293818
Form:       8-K
Filed at:   2023-01-18T23:59:59+00:00
Accession:  0001079973-23-000095
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OpGen reports preliminary 2022 revenue of $2.7M, within guidance; cash $7.4M; raises $7.5M in offering
--------------------------------------------------------------------------------

- Preliminary full-year 2022 revenue approximately $2.7M, within most recent guidance range.
- Cash position as of Dec 31, 2022: $7.4M; closed public offering on Jan 11, 2023 with gross proceeds $7.5M.
- Implemented 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance.
- UTI clinical trial achieved 96.4% sensitivity and 97.4% specificity; preparing FDA submission.
- Signed second Acuitas AMR Gene Panel customer contract and installed first two systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/0001079973-23-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/opgen_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer